Cases & Deals

  • Home
  • Practices
  • Dendreon completes $426.9 million public offering of Common Stock

Share

Dendreon completes $426.9 million public offering of Common Stock

December 2009

Client(s) Dendreon Corporation

Jones Day represented Dendreon Corporation, a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients, in connection with the $426.9 million public offering of Common Stock, underwritten by J.P. Morgan Securities Inc., Deutsche Bank Securities Inc., Citigroup Global Markets Inc., Lazard Capital Markets LLC, Leerink Swann LLC, Morgan Stanley & Co. Incorporated, and Needham & Company LLC.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.